UCB's Global Corporate Website

UCB off to a good start

Posted by
Antje Witte, Investor Relations
It is on days like this, when we publish revenue and selected net sales for the first quarter of the year, that I am reminded of the strength of UCB's growth path – at both current and constant exchange rates, UCB revenue grew by double digits.

And just as this is the result of past R&D, good progress in our pipeline shows encouraging signs for the future.

So what do the numbers say? Revenue was € 895 million in the first quarter of 2015, up 19% (or 11% at constant currencies). € 433 million came from sales of our three core medicines. Sales of these three core products increased by 36% (or 20% at constant currencies).

Our established epilepsy drug also brought in sales of € 190 million (+14%; +4% at constant currencies). These four medicines' net sales represent 70% of our Q1 2015 revenue.

After this good start to the year, I am pleased to say that our financial outlook for 2015 is confirmed. 2015 revenue should reach approximately € 3.55-3.65 billion; recurring EBITDA should increase to approximately € 710-740 million. Core earnings per share (EPS) are expected in the range of € 1.90-2.05 based on an average of 193.7 million shares outstanding.

You can read more about our Q1 interim report, today's Annual Shareholders' Meeting (please note that dividend payment day is May 6) and other information for investors or contact me directly with your feedback.

Now if you'll excuse me I need to get go on the road as I will be seeing some of you in Boston (US), Scandinavia and Brussels  – which are my next destinations for investor outreach: looking forward to continuing the dialogue!